Patents Assigned to Helsinn Healthcare S.A.
  • Publication number: 20140193487
    Abstract: Provided are compositions and methods for treating or preventing nausea and vomiting in patients undergoing chemotherapy, radiotherapy, or surgery.
    Type: Application
    Filed: November 1, 2013
    Publication date: July 10, 2014
    Applicant: Helsinn Healthcare S.A.
    Inventors: Fabio TRENTO, Sergio CANTOREGGI, Giorgia ROSSI, Roberta CANNELLA, Daniele BONADEO
  • Publication number: 20140194438
    Abstract: Provided are compositions and methods for treating or preventing nausea and vomiting in patients undergoing chemotherapy, radiotherapy, or surgery.
    Type: Application
    Filed: November 1, 2013
    Publication date: July 10, 2014
    Applicant: Helsinn Healthcare S.A.
    Inventors: Fabio TRENTO, Sergio CANTOREGGI, Giorgia ROSSI, Roberta CANNELLA, Daniele BONADEO
  • Publication number: 20140194395
    Abstract: Provided are compositions and methods for treating or preventing nausea and vomiting in patients undergoing chemotherapy, radiotherapy, or surgery.
    Type: Application
    Filed: November 1, 2013
    Publication date: July 10, 2014
    Applicant: Helsinn Healthcare S.A.
    Inventors: Fabio TRENTO, Sergio CANTOREGGI, Giorgia ROSSI, Roberta CANNELLA, Daniele BONADEO
  • Publication number: 20140171646
    Abstract: Amorphous and polymorphic of palonosetron hydrochloride are disclosed that can be characterized by X-ray powder diffraction patterns, thermal properties, purity and methods of manufacture. These forms of palonosetron hydrochloride can be produced from solution or by solid state interconversions. The forms can be used in pharmaceutical formulations: particularly preferred uses of these formulations are in prevention and treatment of nausea and emesis arising from chemotherapy or postoperative side effects. The forms can optionally be used as mixtures of the crystalline and/or amorphous forms.
    Type: Application
    Filed: October 2, 2013
    Publication date: June 19, 2014
    Applicant: Helsinn Healthcare S.A.
    Inventors: Waldo MOSSI, Giorgio CALDERARI, Wilma TAMRAZ, Tai Wah CHAN
  • Publication number: 20140097114
    Abstract: The present invention relates to shelf-stable liquid formulations of palonosetron for reducing chemotherapy and radiotherapy induced emesis with palonosetron. The formulations are particularly useful in the preparation of intravenous and oral liquid medicaments.
    Type: Application
    Filed: November 4, 2013
    Publication date: April 10, 2014
    Applicants: Roche Palo Alto LLC, Helsinn Healthcare S.A.
    Inventors: Giorgio Calderari, Daniele Bonadeo, Roberta Cannella, Alberto Macciocchi, Andrew Miksztal, Thomas Malefyt, Kathleen M Lee, Carmine Panuccio
  • Publication number: 20140039000
    Abstract: The present invention relates to shelf-stable liquid formulations of palonosetron for reducing chemotherapy and radiotherapy induced emesis with palonosetron. The formulations are particularly useful in the preparation of intravenous and oral liquid medicaments.
    Type: Application
    Filed: October 14, 2013
    Publication date: February 6, 2014
    Applicants: Roche Palo Alto LLC, Helsinn Healthcare S.A.
    Inventors: Giorgio Calderari, Daniele Bonadeo, Roberta Cannella, Alberto Macciocchi, Andrew Miksztal, Thomas Malefyt, Kathleen M. Lee
  • Patent number: 8623826
    Abstract: Provided are methods for treating nausea and vomiting in patients undergoing chemotherapy, radiotherapy, or surgery, comprising the co-administration of netupitant, palonosetron and dexamethasone.
    Type: Grant
    Filed: March 31, 2011
    Date of Patent: January 7, 2014
    Assignee: Helsinn Healthcare S.A.
    Inventors: Fabio Trento, Sergio Cantoreggi, Giorgia Rossi, Roberta Cannella, Daniele Bonadeo
  • Publication number: 20130261149
    Abstract: The present invention relates to shelf-stable liquid formulations of palonosetron for reducing chemotherapy and radiotherapy induced emesis with palonosetron. The formulations are particularly useful in the preparation of intravenous and oral liquid medicaments.
    Type: Application
    Filed: May 24, 2013
    Publication date: October 3, 2013
    Applicants: Roche Palo Alto LLC, Helsinn Healthcare S.A.
    Inventors: Giorgio Calderari, Daniele Bonadeo, Roberta Cannella, Alberto Macciocchi, Andrew Miksztal, Thomas Malefyt, Kathleen M. Lee
  • Publication number: 20130261592
    Abstract: The present invention relates to shelf-stable liquid formulations of palonosetron for reducing chemotherapy and radiotherapy induced emesis with palonosetron. The formulations are particularly useful in the preparation of intravenous and oral liquid medicaments.
    Type: Application
    Filed: May 23, 2013
    Publication date: October 3, 2013
    Applicants: Roche Palo Alto LLC, Helsinn Healthcare S.A.
    Inventors: Giorgio Calderari, Daniele Bonadeo, Roberta Cannella, Alberto Macciocchi, Andrew Miksztal, Thomas Malefyt, Kathleen M. Lee, Carmine Panuccio
  • Publication number: 20120253046
    Abstract: Provided are metabolites of palonosetron that can be used in treating animals, particularly humans, of the formula (I): or a pharmaceutically acceptable salt or prodrug thereof; wherein R1 and R4 independently can be H, hydroxyl, or carbonyl; and wherein R3 can be Formule (II) or Formule (III).
    Type: Application
    Filed: November 1, 2010
    Publication date: October 4, 2012
    Applicant: Helsinn Healthcare S.A.
    Inventor: Waldo Mossi
  • Publication number: 20110192493
    Abstract: The present invention relates to shelf-stable liquid formulations of palonosetron for reducing chemotherapy and radiotherapy induced emesis with palonosetron. The formulations are particularly useful in the preparation of intravenous and oral liquid medicaments.
    Type: Application
    Filed: April 14, 2011
    Publication date: August 11, 2011
    Applicants: Helsinn Healthcare S.A., Roche Palo Alto LLC
    Inventors: Giorgio Calderari, Daniele Bonadeo, Roberta Cannella, Enrico Braglia, Riccardo Braglia, Andrew Miksztal, Thomas Malefyt, Kathleen M. Lee
  • Patent number: 7960424
    Abstract: The present invention relates to shelf-stable liquid formulations of palonosetron for reducing chemotherapy and radiotherapy induced emesis with palonosetron. The formulations are particularly useful in the preparation of intravenous and oral liquid medicaments.
    Type: Grant
    Filed: March 24, 2006
    Date of Patent: June 14, 2011
    Assignees: Helsinn Healthcare S.A., Roche Palo Alto LLC
    Inventors: Giorgio Calderari, Daniele Bonadeo, Roberta Cannella, Enrico Braglia, Riccardo Braglia, Andrew Miksztal, Thomas Malefyt, Kathleen M. Lee
  • Patent number: 7947724
    Abstract: The present invention relates to shelf-stable liquid formulations of palonosetron for reducing chemotherapy and radiotherapy induced emesis with palonosetron. The formulations are particularly useful in the preparation of intravenous and oral liquid medicaments.
    Type: Grant
    Filed: July 21, 2005
    Date of Patent: May 24, 2011
    Assignees: Helsinn Healthcare S.A., Roche Palo Alto LLC
    Inventors: Giorgio Calderari, Daniele Bonadeo, Roberta Cannella, Enrico Braglia, Riccardo Braglia, Andrew Miksztal, Thomas Malefyt, Kathleen M. Lee
  • Patent number: 7947725
    Abstract: The present invention relates to shelf-stable liquid formulations of palonosetron for reducing chemotherapy and radiotherapy induced emesis with palonosetron. The formulations are particularly useful in the preparation of intravenous and oral liquid medicaments.
    Type: Grant
    Filed: March 24, 2006
    Date of Patent: May 24, 2011
    Assignees: Helsinn Healthcare S.A., Roche Palo Alto LLC
    Inventors: Giorgio Calderari, Daniele Bonadeo, Roberta Cannella, Enrico Braglia, Riccardo Braglia, Andrew Miksztal, Thomas Malefyt, Kathleen M. Lee
  • Publication number: 20100261734
    Abstract: The present invention relates to methods for reducing the frequency of bladder contractions without significantly affecting micturition pressure, comprising administering a pharmaceutical composition comprising a therapeutically effective amount of netupitant, or a pharmaceutically acceptable salt or prodrug thereof. The method can be used to treat bladder dysfunction without significantly increasing residual volume, including urgency, frequency, pollakiuria, nocturia, low deferment time, suboptimal volume threshold, neurogenic bladder, or combinations thereof.
    Type: Application
    Filed: April 12, 2010
    Publication date: October 14, 2010
    Applicant: Helsinn Healthcare S.A.
    Inventors: Claudio Pietra, Sergio Cantoreggi, Riccardo Braglia
  • Publication number: 20030036563
    Abstract: The present invention relates to nimesulide topical formulations comprising a carboxyvinylpolymer neutralized as a gel-forming agent or a polyacrylamide-isoparaffin and a solvent selected from the group consisting of ethanol, isopropanol and diethylene glycol monoethyl ether, and to the process for the preparation thereof. Said formulations have advantages such as higher stability of the system and bioavailability of the active ingredient.
    Type: Application
    Filed: September 26, 2002
    Publication date: February 20, 2003
    Applicant: HELSINN HEALTHCARE S.A.
    Inventors: Stefano Bader, Enrique Hausermann, Tiziana Monti
  • Patent number: 6288121
    Abstract: Nimesulide topical formulations are provided in the form of liquid crystals. The emulsifier cetylstearyl glycoside is used, and constituents of the lipid phase such as caprylic/capric triglycerides and jojoba oil, consistence factors such as cetylstearyl alcohol. Also disclosed is a process for the preparation thereof. The formulations have advantages such as higher stability, better release and absorption of nimesulide, and a higher bioavailability of the active ingredient.
    Type: Grant
    Filed: August 4, 1999
    Date of Patent: September 11, 2001
    Assignee: Helsinn Healthcare S.A.
    Inventors: Stefano Bader, Enrique Hausermann, Tiziana Monti
  • Patent number: 5837735
    Abstract: An antiinflammatory agent for external use, containing nimesulide as the active ingredient dispersed in the base component and being well absorbable, safe and discoloration-free.
    Type: Grant
    Filed: July 10, 1997
    Date of Patent: November 17, 1998
    Assignee: Helsinn Healthcare S.A.
    Inventors: Satoru Miyata, Yasuaki Taniguchi, Kenji Masuda, Yoichi Kawamura
  • Patent number: D665072
    Type: Grant
    Filed: September 8, 2011
    Date of Patent: August 7, 2012
    Assignee: Helsinn Healthcare S.A.
    Inventors: Fabio Trento, Sergio Cantoreggi, Giorgia Rossi, Roberta Cannella, Daniele Bonadeo, Riccardo Braglia